Assessment Status |
Awaiting response from Applicant |
HTA ID |
22021 |
Drug |
Ciltacabtagene autoleucel |
Brand |
Carvykti® |
Indication |
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
Rapid review commissioned |
11/04/2022 |
Rapid review completed |
12/05/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care. |
Full pharmacoeconomic assessment commissioned by HSE |
27/05/2022 |
Pre-submission consultation with Applicant |
12/07/2022 |
Full submission received from Applicant |
30/11/2022 |
Preliminary review sent to Applicant |
30/05/2023 |